{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Clarke KEN"],"pubmed_abstract":["<h4>Background and objectives</h4>Trends in estimates of US pediatric SARS-CoV-2 infection-induced seroprevalence from commercial laboratory specimens may overrepresent children with frequent healthcare needs. We examined seroprevalence trends and compared seroprevalence estimates by testing type and diagnostic coding.<h4>Methods</h4>Cross-sectional convenience samples of residual sera between September 2021 and February 2022 from 52 U.S. jurisdictions were assayed for infection-induced SARS-CoV-2 antibodies; monthly seroprevalence estimates were calculated by age group. Multivariate logistic analyses compared seroprevalence estimates for specimens associated with ICD-10 codes and laboratory orders indicating well-child care with estimates for other pediatric specimens.<h4>Results</h4>Infe"],"journal":["The Journal of infectious diseases"],"pagination":["jiac423"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9620360"],"repository":["biostudies-literature"],"pubmed_title":["Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical Care-September 2021-February 2022."],"pmcid":["PMC9620360"],"pubmed_authors":["MacNeil A","Gundlapalli AV","Lee A","Jones J","Iachan R","Nycz E","Kim Y","Hall A","Clarke KEN","Deng Y"],"additional_accession":[]},"is_claimable":false,"name":"Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical Care-September 2021-February 2022.","description":"<h4>Background and objectives</h4>Trends in estimates of US pediatric SARS-CoV-2 infection-induced seroprevalence from commercial laboratory specimens may overrepresent children with frequent healthcare needs. We examined seroprevalence trends and compared seroprevalence estimates by testing type and diagnostic coding.<h4>Methods</h4>Cross-sectional convenience samples of residual sera between September 2021 and February 2022 from 52 U.S. jurisdictions were assayed for infection-induced SARS-CoV-2 antibodies; monthly seroprevalence estimates were calculated by age group. Multivariate logistic analyses compared seroprevalence estimates for specimens associated with ICD-10 codes and laboratory orders indicating well-child care with estimates for other pediatric specimens.<h4>Results</h4>Infe","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-05T11:57:17.4Z","creation":"2025-02-19T03:59:25.305Z"},"accession":"S-EPMC9620360","cross_references":{"pubmed":["36281757"],"doi":["10.1093/infdis/jiac423"]}}